Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Neurogenic Detrusor Overactivity Market Forecast: Value Set To Climb From $1.96 Billion To $2.63 Billion
The neurogenic detrusor overactivity market size has observed substantial growth in recent years. It is anticipated to increase from $1.82 billion in 2025 to $1.97 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. This historical expansion can be linked to factors such as restricted treatment options for NDO, a reliance on conventional surgical interventions, a rising prevalence of neurogenic bladder disorders, expanding hospital and urology clinic infrastructure, and insufficient patient and caregiver education.
The market size for neurogenic detrusor overactivity is anticipated to exhibit substantial growth over the next few years. It is projected to expand to $2.63 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.6%. This expansion during the forecast period can be attributed to the development of innovative pharmacological treatments, advancements in minimally invasive surgical methods, the integration of neuromodulation devices, increased uptake of continuous patient monitoring technologies, and rising investments in long-term care and rehabilitation services. Prominent trends expected in this period include the growing adoption of antimuscarinic and beta-3 adrenergic agonists, a greater reliance on neuromodulation and less invasive therapies, the expansion of behavioral therapy and patient training programs, an increasing focus on urodynamic and ultrasound monitoring, and heightened awareness of quality of life assessment and long-term care options.
Get A Free Sample Report With In-Depth Market Insights:
Neurogenic Detrusor Overactivity Market Growth Backed By Core Demand Fundamentals
The increasing prevalence of neurological disorders is anticipated to fuel the expansion of the neurogenic detrusor overactivity market in the coming years. Neurological disorders are medical conditions that impact the brain, spinal cord, or nerves, resulting in issues with movement, sensation, cognition, or other bodily functions. These disorders are becoming more common as individuals live longer, which heightens the probability of age-related brain deterioration. Neurogenic detrusor overactivity (NDO) is a type of bladder dysfunction frequently linked to neurological conditions such as spinal cord injury, multiple sclerosis, and Parkinson’s disease. These ailments disrupt the normal nerve communication between the brain and bladder, leading to involuntary bladder contractions. For example, in April 2024, a study published by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, projected an estimated 4.9 billion cases of brain disorders globally by 2050, representing a 22% increase from approximately 4 billion cases recorded in 2021. Therefore, the rising incidence of neurological disorders is driving growth in the neurogenic detrusor overactivity market.
Neurogenic Detrusor Overactivity Market Segment Breakdown: Which Categories Lead On Revenue?
The neurogenic detrusor overactivity market covered in this report is segmented –
1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
2) By Application: Adult, Child
3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
Subsegments:
1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
Neurogenic Detrusor Overactivity Market Growth Trends Reshaping The Competitive Landscape
Key companies operating within the neurogenic detrusor overactivity (NDO) treatment market are focusing their efforts on developing sophisticated generic therapeutics, such as beta-3 adrenergic receptor agonists, aiming to deliver effective bladder control solutions at reduced costs. Beta-3 adrenergic receptor agonists, including mirabegron, work by relaxing the detrusor muscle in the bladder, which in turn increases bladder capacity and diminishes symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an India-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (USFDA) for the launch of Mirabegron, the generic version of Myrbetriq, in the United States. As an advanced once-daily oral therapy, Mirabegron provides a convenient and effective treatment option for patients experiencing overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) in pediatric populations. This approval further solidifies Lupin’s commitment to broadening access to high-quality, affordable generic medications in crucial therapeutic areas.
Neurogenic Detrusor Overactivity Market Leading Players And Competitive Positioning
Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.
View The Full Neurogenic Detrusor Overactivity Market Report:
Neurogenic Detrusor Overactivity Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
